Levemir Flexpen100 IU/ml

Levemir Flexpen is a long-acting (basal) human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus who require basal insulin therapy.

Established/FDA-approved uses

• Type 1 diabetes mellitus, in adults and children 2 years of age and older, as part of a basal-bolus insulin regimen.
• Type 2 diabetes mellitus in adults, as basal insulin therapy alone or in combination with oral antidiabetic agents and/or bolus (mealtime) insulin, when oral agents alone do not achieve adequate glycemic control.

Not indicated for

• Levemir Flexpen is not indicated for the treatment of diabetic ketoacidosis; rapid-acting intravenous insulin is required for that condition.
• Levemir Flexpen is not for intravenous or intramuscular administration and does not replace short-acting mealtime insulin when prandial coverage is needed.

Each milliliter of the injectable solution contains Insulin Detemir (rDNA origin) 100 units, together with pharmaceutical excipients (such as phenol, metacresol, zinc acetate, glycerol, disodium phosphate dihydrate, and water for injection) forming a clear, colorless, neutral aqueous solution for subcutaneous injection. It is typically supplied in pre-filled pens or vials.

Levemir Flexpen is a soluble, long-acting basal insulin analog produced by recombinant DNA technology. A fatty acid (myristic acid) side chain attached to the insulin molecule allows it to bind reversibly to albumin after subcutaneous injection, slowing its absorption and giving a relatively flat, prolonged glucose-lowering effect compared with human NPH insulin. Levemir Flexpen is used to help control blood glucose in people with type 1 and type 2 diabetes mellitus as part of an overall management plan that includes diet, exercise, and glucose monitoring.

Long-acting (basal) insulin analog; antidiabetic agent used for glycemic control. Levemir Flexpen belongs to the insulin class of hormonal antidiabetic medicines.

Mechanism of Action

Insulin Detemir lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating cellular glucose uptake, and by inhibiting hepatic glucose output. Its prolonged action results from reversible albumin binding via its fatty acid side chain, which delays absorption from the subcutaneous depot and slows systemic distribution.

Pharmacokinetics

• Onset: approximately 1-2 hours after subcutaneous injection.
• Duration of action: dose-dependent, typically 6-24 hours, often given once or twice daily.
• Profile: relatively flat, with a less pronounced peak than NPH insulin, which reduces (but does not eliminate) the risk of hypoglycemia between doses.
• Protein binding: greater than 98% bound to plasma albumin.

Levemir Flexpen is for subcutaneous injection only; it must never be given intravenously or intramuscularly.

• Inject subcutaneously into the thigh, upper arm, abdominal wall, or gluteal region.
• Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.
• Inspect the solution before use; it should be clear and colorless. Do not use if it looks cloudy, discolored, or contains particles.
• Do not dilute or mix Levemir Flexpen with other insulin products in the same syringe unless specifically directed by a physician, as this may alter its time-action profile.
• Follow the instructions provided with the pen or vial device and use a new needle for each injection.

Clinically Significant Interactions

The most common and most serious adverse effect of Levemir Flexpen is hypoglycemia (see Precautions and Warnings). Other reported side effects include:

• Injection site reactions (redness, swelling, itching, pain).
• Lipodystrophy (lipohypertrophy or lipoatrophy) at repeated injection sites.
• Weight gain.
• Peripheral edema, especially when starting insulin therapy or intensifying glucose control.
• Allergic reactions, uncommon but ranging from local rash to rare systemic reactions.
• Pruritus and rash.

Pregnancy

Insulin therapy, including Levemir Flexpen, is a preferred option for achieving glycemic control during pregnancy when pharmacologic treatment is needed, since insulin does not cross the placenta in clinically significant amounts. Levemir Flexpen should nonetheless be used only if clearly needed and under close medical supervision, as insulin requirements often change during each trimester and postpartum; consult a physician.

Lactation

Insulin, including Levemir Flexpen, is generally considered compatible with breastfeeding, as it is not expected to be orally bioavailable to the infant in clinically relevant amounts. Maternal dose may need adjustment during lactation; consult a physician before use.

Hypoglycemia

Hypoglycemia is the most common and most serious risk with all insulin therapy, including Levemir Flexpen. Risk increases with skipped meals, exercise, alcohol use, and renal/hepatic impairment. Educate patients to recognize symptoms (sweating, tremor, confusion, palpitations) and to carry a fast-acting source of glucose.

Not for Diabetic Ketoacidosis

Levemir Flexpen is not for intravenous use and must not be used to treat diabetic ketoacidosis, which requires rapid-acting intravenous insulin.

Hypokalemia

All insulins, including Levemir Flexpen, shift potassium from plasma into cells and can cause hypokalemia; untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium in at-risk patients.

Injection Site Reactions and Lipodystrophy

Repeated injection at the same site without rotation can lead to lipodystrophy and altered local absorption. Rotate injection sites regularly.

Dose Titration and Monitoring

Levemir Flexpen requires individualized dose titration and regular self-monitoring of blood glucose; changes in diet, activity, illness, organ function, or concomitant medication may necessitate dose adjustment.

Fluid Retention with Concomitant TZD Use

See Interactions for the increased risk of fluid retention and heart failure when Levemir Flexpen is combined with thiazolidinediones.

Do Not Share Devices

Pens and needles must never be shared between patients, even with a new needle, due to the risk of transmitting blood-borne pathogens.

Overdose of Levemir Flexpen relative to food intake, energy expenditure, or other glucose-lowering therapy can cause hypoglycemia, presenting as sweating, tremor, palpitations, confusion, seizures, or loss of consciousness. Mild-to-moderate episodes are usually managed with oral fast-acting carbohydrate. Severe hypoglycemia with unconsciousness or seizures is a medical emergency: seek immediate medical attention or contact emergency services, as glucagon or intravenous glucose administered by a trained caregiver or healthcare professional may be required. Do not attempt to manage a severe overdose at home without professional guidance.

Store unopened Levemir Flexpen pens/vials in a refrigerator (2°C-8°C); do not freeze, and discard if it has been frozen. Once in use, the pen/vial may be kept at room temperature (below 30°C), away from direct heat and light, for up to 42 days, after which it should be discarded even if medicine remains. Keep out of reach of children.

Renal Impairment

Insulin requirements may be reduced due to decreased insulin clearance; monitor glucose closely and adjust the Levemir Flexpen dose as needed.

Hepatic Impairment

Insulin requirements may be reduced due to decreased gluconeogenesis and insulin metabolism; monitor glucose closely.

Elderly

Use with caution in elderly patients due to increased sensitivity to hypoglycemia and possible impaired recognition of hypoglycemic symptoms; conservative dose titration of Levemir Flexpen is recommended.

Pediatric

See Pediatric Uses.

Pregnancy and Lactation

See Pregnancy and Lactation section above.

Levemir Flexpen is generally used as long-term, ongoing basal insulin therapy for chronic management of diabetes mellitus; there is no fixed treatment duration. Continued need, dose, and regimen should be reassessed periodically by the treating physician based on glycemic control (e.g., HbA1c), health status, and treatment goals.

Insulins; long-acting (basal) insulin analogs; antidiabetic agents. Insulin Detemir is classified within the insulin therapeutic class used in the pharmacologic management of diabetes mellitus.

Insulin Detemir acts by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and by suppressing hepatic glucose production, similarly to endogenous insulin. Its distinguishing feature is a C14 fatty acid (myristic acid) side chain attached at the lysine residue of the insulin B-chain, which enables reversible albumin binding at the subcutaneous injection site and in circulation. This albumin binding slows absorption and delays clearance, producing a prolonged, relatively peakless duration of action compared with regular human insulin or NPH insulin.

B

The safety and efficacy of Levemir Flexpen have been established in children and adolescents 2 years of age and older with type 1 diabetes mellitus; dosing is individualized in the same manner as for adults, under the supervision of a physician experienced in pediatric diabetes management.

Safety and efficacy of Levemir Flexpen in children younger than 2 years of age, and in pediatric patients with type 2 diabetes mellitus, have not been established.